MA41756A - Procédés et compositions utiles dans la génération de réponses non canoniques de lymphocytes t cd8+ - Google Patents
Procédés et compositions utiles dans la génération de réponses non canoniques de lymphocytes t cd8+Info
- Publication number
- MA41756A MA41756A MA041756A MA41756A MA41756A MA 41756 A MA41756 A MA 41756A MA 041756 A MA041756 A MA 041756A MA 41756 A MA41756 A MA 41756A MA 41756 A MA41756 A MA 41756A
- Authority
- MA
- Morocco
- Prior art keywords
- protein
- methods
- antigen
- canonic
- heterologous
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 12
- 108090000623 proteins and genes Proteins 0.000 abstract 12
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 230000005867 T cell response Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y117/00—Oxidoreductases acting on CH or CH2 groups (1.17)
- C12Y117/04—Oxidoreductases acting on CH or CH2 groups (1.17) with a disulfide as acceptor (1.17.3)
- C12Y117/04001—Ribonucleoside-diphosphate reductase (1.17.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
Abstract
L'invention concerne des procédés d'induction d'une réponse de lymphocytes t cd8 + à un antigène hétérologue dans lequel au moins 10% des lymphocytes t cd8 + sont restreints par le cmh-e. La méthode consiste à immuniser avec un vecteur cmv qui n'exprime pas les protéines ul128 et ul130. L'invention concerne également des vecteurs cmv recombinants comprenant des acides nucléiques codant pour un antigène protéique hétérologue, une protéine ul40 et une protéine us28, mais n'exprimant pas une protéine active ul128 et ul130. L'invention concerne également des vecteurs cmv recombinants comprenant des acides nucléiques codant pour un antigène protéique hétérologue, mais n'exprimant pas une protéine ul40 active, une protéine ul128, une protéine ul130 et, facultativement, une protéine us28. L'invention concerne également des vecteurs cmv recombinants comprenant des acides nucléiques codant pour un antigène protéique hétérologue, mais n'exprimant pas une protéine us28 active, une protéine ul128, une protéine ul130 et éventuellement une protéine ul40.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562114203P | 2015-02-10 | 2015-02-10 | |
US201562196520P | 2015-07-24 | 2015-07-24 | |
US201562220703P | 2015-09-18 | 2015-09-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41756A true MA41756A (fr) | 2017-12-20 |
Family
ID=56615684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041756A MA41756A (fr) | 2015-02-10 | 2016-02-10 | Procédés et compositions utiles dans la génération de réponses non canoniques de lymphocytes t cd8+ |
Country Status (15)
Country | Link |
---|---|
US (2) | US20180298404A1 (fr) |
EP (2) | EP4036239A1 (fr) |
JP (3) | JP6816031B2 (fr) |
KR (1) | KR20170136512A (fr) |
CN (2) | CN108064304A (fr) |
AU (1) | AU2016219317A1 (fr) |
BR (1) | BR112017017092A2 (fr) |
CA (1) | CA2976245A1 (fr) |
EA (1) | EA201791806A1 (fr) |
HK (2) | HK1247638A1 (fr) |
IL (1) | IL253935B (fr) |
MA (1) | MA41756A (fr) |
MX (1) | MX2017010027A (fr) |
SG (1) | SG11201706454VA (fr) |
WO (1) | WO2016130693A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2569436T (lt) | 2010-05-14 | 2018-03-12 | Oregon Health & Science University | Rekombinantiniai žcmv ir hcmv vektoriai ir jų panaudojimas |
SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
CA2904001C (fr) | 2013-03-05 | 2021-07-13 | Oregon Health & Science University | Vecteurs cytomegalovirus permettant la commande du ciblage de lymphocyte t |
WO2015048744A2 (fr) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
WO2016011293A1 (fr) | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Cytomégalovirus humain comprenant des antigènes exogènes |
CN108064304A (zh) | 2015-02-10 | 2018-05-22 | 俄勒冈健康与科学大学 | 可用于产生非典型cd8+ t细胞应答的方法和组合物 |
EP3364981A4 (fr) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Vaccin contre le cytomégalovirus humain |
EP3377636A4 (fr) | 2015-11-20 | 2019-11-06 | Oregon Health & Science University | Vecteurs cmv comprenant des éléments de reconnaissance des microarn |
US20200182884A1 (en) | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
CN110036112B (zh) | 2016-10-18 | 2024-05-10 | 俄勒冈健康与科学大学 | 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体 |
WO2018075980A1 (fr) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Vaccin contre le cytomégalovirus humain |
EP3539552A1 (fr) * | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation et expansion de cellules nk nkg2c+ |
AU2019338307A1 (en) * | 2018-09-10 | 2021-04-15 | Atara Biotherapeutics, Inc. | Methods for expanding antigen-specific CAR-T cells, compositions and uses related thereto |
US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
US10632186B1 (en) | 2019-03-21 | 2020-04-28 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
WO2020188111A1 (fr) * | 2019-03-21 | 2020-09-24 | 21C Bio | Vaccin contre des cellules de l'activation immunitaire pathogène au cours d'infections |
CN110055228B (zh) * | 2019-04-17 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 用于乙肝病毒感染的重组巨细胞病毒与应用 |
WO2020247859A2 (fr) * | 2019-06-07 | 2020-12-10 | Oregon Health & Science University | Réponses de lymphocytes t spécifiques d'un antigène associé à une tumeur |
MX2022002154A (es) * | 2019-08-20 | 2022-03-17 | Univ Oregon Health & Science | Modulacion de las respuestas de celulas t por ul18 del citomegalovirus humano. |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
TW202311531A (zh) | 2021-08-31 | 2023-03-16 | 美商維爾生物科技股份有限公司 | 重組hcmv載體及其用途 |
TW202328167A (zh) | 2021-08-31 | 2023-07-16 | 美商維爾生物科技股份有限公司 | 結核病疫苗 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
ATE118822T1 (de) | 1987-06-26 | 1995-03-15 | Syntro Corp | Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung. |
SG49046A1 (en) | 1991-07-05 | 1998-05-18 | American Cyanamid Co | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus |
WO1995003399A2 (fr) | 1993-07-19 | 1995-02-02 | Cantab Pharmaceuticals Research Limited | Procede de production destine a la preparation de virus neutralises |
AU2234995A (en) | 1994-04-29 | 1995-11-29 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
ATE324435T1 (de) | 1995-02-21 | 2006-05-15 | Cantab Pharmaceuticals Res Ltd | Virale zubereitungen, vektoren, immunogene und impfstoffe |
EP0820311A4 (fr) | 1995-04-04 | 2002-09-25 | Cell Genesys Inc | Transplantation de cellules genetiquement modifiees presentant de faibles taux de proteines de classe i du complexe majeur d'histocompatibilite sur leur surface |
AU730351B2 (en) | 1996-07-31 | 2001-03-08 | Ortho-Mcneil Pharmaceutical, Inc. | Identification of human cytomegalovirus genes involved in down-regulation of MHC class I heavy chain expression |
US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
WO1999007869A1 (fr) | 1997-08-05 | 1999-02-18 | University Of Florida | Vaccin vivant recombinant comprenant un virus ne se repliquant pas ou se repliquant sans efficacite |
US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
US6740324B2 (en) * | 2001-02-02 | 2004-05-25 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
US20040087001A1 (en) | 2001-02-21 | 2004-05-06 | Gabriele Hahn | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
US20070015721A1 (en) | 2001-09-20 | 2007-01-18 | Andrew Beaton | Hiv-gag codon-optimised dna vaccines |
US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
AU2003228792A1 (en) | 2002-04-30 | 2003-11-17 | Avior Therapeutics, Inc. | Adenovirus vectors for immunotherapy |
DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
US7407744B2 (en) | 2003-07-25 | 2008-08-05 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors |
WO2006031264A2 (fr) | 2004-05-25 | 2006-03-23 | Oregon Health And Science University | Vaccination du virus de l'immunodeficience simienne (siv) et du virus de l'immunodeficience humaine (vih) utilisant des vecteurs de vaccin a base de rhcmv et hcmv |
EP1602676A1 (fr) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Compositions catalytiques |
WO2006004661A1 (fr) | 2004-06-25 | 2006-01-12 | Medimmune Vaccines, Inc. | Cytomegalovirus humain de recombinaison et vaccins contenant des antigenes heterologues |
EP1888622A1 (fr) | 2005-05-23 | 2008-02-20 | Oxxon Therapeutics Ltd. | Compositions permettant d'induire une réponse immunitaire contre l'hépatite b |
US8765146B2 (en) | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
US20100142823A1 (en) | 2007-03-07 | 2010-06-10 | Ze Wang | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
JP2012519484A (ja) | 2009-03-06 | 2012-08-30 | マウント・シナイ・スクール・オヴ・メディシン | マイクロrna応答要素を含む弱毒化生インフルエンザウイルスワクチン |
MX2012007489A (es) | 2009-12-23 | 2012-11-29 | 4Antibody Ag | Miembros enlazadores para citomegalovirus. |
WO2011093858A1 (fr) | 2010-01-27 | 2011-08-04 | Oregon Health & Science University | Préparations immunogènes à base de cytomégalovirus |
ES2625406T3 (es) | 2010-03-25 | 2017-07-19 | Oregon Health & Science University | Glicoproteínas de CMV y vectores recombinantes |
EP2566957B8 (fr) | 2010-05-05 | 2018-06-06 | Sirion Biotech GmbH | Vaccin contre une infection à virus herpès bêta et utilisation correspondante |
LT2569436T (lt) * | 2010-05-14 | 2018-03-12 | Oregon Health & Science University | Rekombinantiniai žcmv ir hcmv vektoriai ir jų panaudojimas |
SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
CA2904001C (fr) | 2013-03-05 | 2021-07-13 | Oregon Health & Science University | Vecteurs cytomegalovirus permettant la commande du ciblage de lymphocyte t |
WO2016011293A1 (fr) | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Cytomégalovirus humain comprenant des antigènes exogènes |
EP3048114A1 (fr) | 2015-01-22 | 2016-07-27 | Novartis AG | Antigènes du cytomégalovirus et leurs utilisations |
CN108064304A (zh) | 2015-02-10 | 2018-05-22 | 俄勒冈健康与科学大学 | 可用于产生非典型cd8+ t细胞应答的方法和组合物 |
EP3377636A4 (fr) | 2015-11-20 | 2019-11-06 | Oregon Health & Science University | Vecteurs cmv comprenant des éléments de reconnaissance des microarn |
CN109843321A (zh) | 2016-06-22 | 2019-06-04 | 国际艾滋病疫苗行动组织公司 | 作为结核病疫苗的重组巨细胞病毒载体 |
US20200182884A1 (en) | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
CN110036112B (zh) | 2016-10-18 | 2024-05-10 | 俄勒冈健康与科学大学 | 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体 |
-
2016
- 2016-02-10 CN CN201680014682.9A patent/CN108064304A/zh active Pending
- 2016-02-10 CA CA2976245A patent/CA2976245A1/fr not_active Abandoned
- 2016-02-10 EP EP21205026.4A patent/EP4036239A1/fr active Pending
- 2016-02-10 WO PCT/US2016/017373 patent/WO2016130693A1/fr active Application Filing
- 2016-02-10 KR KR1020177025544A patent/KR20170136512A/ko not_active Application Discontinuation
- 2016-02-10 MA MA041756A patent/MA41756A/fr unknown
- 2016-02-10 CN CN202111437865.0A patent/CN114317611A/zh active Pending
- 2016-02-10 EA EA201791806A patent/EA201791806A1/ru unknown
- 2016-02-10 BR BR112017017092A patent/BR112017017092A2/pt not_active Application Discontinuation
- 2016-02-10 EP EP16749813.8A patent/EP3256595A4/fr not_active Withdrawn
- 2016-02-10 US US15/549,814 patent/US20180298404A1/en not_active Abandoned
- 2016-02-10 SG SG11201706454VA patent/SG11201706454VA/en unknown
- 2016-02-10 AU AU2016219317A patent/AU2016219317A1/en not_active Abandoned
- 2016-02-10 JP JP2017560883A patent/JP6816031B2/ja active Active
- 2016-02-10 MX MX2017010027A patent/MX2017010027A/es unknown
-
2017
- 2017-08-09 IL IL253935A patent/IL253935B/en unknown
-
2018
- 2018-05-28 HK HK18106974.7A patent/HK1247638A1/zh unknown
- 2018-10-11 HK HK18113013.6A patent/HK1254041A1/zh unknown
-
2020
- 2020-01-09 US US16/738,178 patent/US11091779B2/en active Active
- 2020-12-23 JP JP2020213267A patent/JP2021121185A/ja active Pending
-
2022
- 2022-08-08 JP JP2022126096A patent/JP2022166122A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2016219317A1 (en) | 2017-08-31 |
JP6816031B2 (ja) | 2021-01-20 |
US11091779B2 (en) | 2021-08-17 |
JP2021121185A (ja) | 2021-08-26 |
SG11201706454VA (en) | 2017-09-28 |
IL253935A0 (en) | 2017-10-31 |
US20200392534A1 (en) | 2020-12-17 |
JP2018510650A (ja) | 2018-04-19 |
MX2017010027A (es) | 2018-08-15 |
AU2016219317A8 (en) | 2017-09-14 |
HK1247638A1 (zh) | 2018-09-28 |
WO2016130693A9 (fr) | 2016-09-15 |
EP3256595A4 (fr) | 2018-09-26 |
IL253935B (en) | 2022-06-01 |
KR20170136512A (ko) | 2017-12-11 |
US20180298404A1 (en) | 2018-10-18 |
WO2016130693A1 (fr) | 2016-08-18 |
HK1254041A1 (zh) | 2019-07-12 |
BR112017017092A2 (pt) | 2018-06-26 |
EP3256595A1 (fr) | 2017-12-20 |
EA201791806A1 (ru) | 2017-12-29 |
CN108064304A (zh) | 2018-05-22 |
EP4036239A1 (fr) | 2022-08-03 |
JP2022166122A (ja) | 2022-11-01 |
CN114317611A (zh) | 2022-04-12 |
CA2976245A1 (fr) | 2016-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41756A (fr) | Procédés et compositions utiles dans la génération de réponses non canoniques de lymphocytes t cd8+ | |
AU2019283892A1 (en) | Anti-human papillomavirus 16 E7 T cell receptors | |
CY1120987T1 (el) | Cmv γλυκοπρωτεϊνες και ανασυνδυασμενοι φορεις | |
GT201700162A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
MY190209A (en) | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same | |
EP4223784A3 (fr) | Compositions et procédés pour moduler une réponse immunitaire à médiation par des lymphocytes t | |
EA201400912A1 (ru) | Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе | |
MX2018015755A (es) | Proteinas de hemaglutinina de virus de influenza y usos de las mismas. | |
SG10201901735XA (en) | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine | |
EP4303229A3 (fr) | Capacité améliorée de présentation de l'antigène de lymphocytes t de récepteur d'antigène chimérique (car) par l'introduction conjointe de molécules de stimulation conjointe | |
MX2018007842A (es) | Nueva generacion de tcr especificos de antigeno. | |
WO2015142671A3 (fr) | Vecteurs du virus de la grippe et leurs utilisations | |
MA43794B1 (fr) | Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie | |
EA201890042A1 (ru) | Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) | |
WO2016191641A3 (fr) | Procédés pour améliorer des réponses immunitaires spécifiques à un antigène à l'aide d'une polythérapie comprenant des antigènes de capside de papillomavirus | |
ZA201603187B (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
MA50280A (fr) | Procédés et compositions pour améliorer l'immunogénicité de tumeurs [ | |
WO2016116905A9 (fr) | Antigènes de cmv et leurs utilisations | |
Kleemann et al. | Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation | |
MX2017001742A (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9. | |
MX2018000023A (es) | Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina. | |
WO2006110915A3 (fr) | Formulations de vaccins pour leishmania | |
MA40371A (fr) | Sélectivité efficace des protéines recombinées | |
FR3001729B1 (fr) | Mutants du facteur x | |
FR3016888B1 (fr) | Synthetases de la colistine et cluster de genes correspondants |